Attacks on access to abortion pills and Covid-19 vaccines are on the rise, opening the door to battles over other government-approved products and therapies. Drugmakers will likely be on high alert for the outcomes of battles to drug access, attorneys say, noting the threat of uncertainty for investors. The idea that a pharmaceutical company could be roped into litigation “is a pretty chilling prospect,” said Susan Lee, Life Sciences partner who advises biologic and drug makers on FDA regulations. “You can be mired in this kind of litigation for a long time, and it’s extremely costly,” Lee said to Bloomberg Law, adding that it could also “raise questions among patients and doctors” about the product’s safety and efficacy.